Zydus Cadila gets four US FDA approvals

Zydus Cadila has received four product approvals from US FDA. The group has received approvals to market Pravastatin' sodium tablets USP 10, 20, 40 and 80 mg and tentative approvals for Escitalopram Oxalate' tablets 5,10 and 20 mg, Losartan Potassium and Hydrochlorthiazide tablets 50 mgIl2.5 mg and 100 mgtl5 mg and Anastrazole tablets 1mg.

The US market of Pravatatin Sodium tablets, a lipid lowering agent which falls in the cardiovascular segment was estimated at US $1.9 billion in 2007. While the branded sales of Escitalopram Oxalate tablet, an anti - depressant was estimated at US $3 billions. Losartan potassium and hydrochlorthiazide tablets an anti hypertensive was estimated at US $785 million and that of Anastrazolc tablets, a hormone therapy to treat breast cancer, was estimated US $813 million in 2007 as per NDC.